Sanofi: presents opportunities for Duxipent
(CercleFinance.com) - Sanofi states that it will present the growth opportunities and development strategy of Dupixent (dupilumab) in type 2 inflammatory diseases, as part of five sessions presenting the development of its R&D portfolio.
It anticipates Dupixent to post strong growth and has set itself the target of achieving over 10 billion euros in sales for this drug, whose single action plays a key role in type 2 inflammation in multiple diseases.
"Recent evidence further supports additional clinical uses in diseases driven by type 2 inflammation including Eosinophilic Esophagitis and a subset of Chronic Obstructive Pulmonary Disease," Sanofi said.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
It anticipates Dupixent to post strong growth and has set itself the target of achieving over 10 billion euros in sales for this drug, whose single action plays a key role in type 2 inflammation in multiple diseases.
"Recent evidence further supports additional clinical uses in diseases driven by type 2 inflammation including Eosinophilic Esophagitis and a subset of Chronic Obstructive Pulmonary Disease," Sanofi said.
Copyright (c) 2020 CercleFinance.com. All rights reserved.